Vismodegib

Vismodegib (Erivedge, Roche Registration GmbH) has 2 EU-approved indications in 1 tumour type.
Approved indications of Vismodegib
Biomarker requirementRegimenSettingConditions
Basal cell carcinoma2
None
Monotherapy
Any line
metastatic
Symptomatic
None
Monotherapy
Any line
locally adv.
Inappropriate for surgery or radiotherapy
Full text of section 4.1 (therapeutic indications)

Erivedge is indicated for the treatment of adult patients with: symptomatic metastatic basal cell carcinoma locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy (see section 5.1).

Label history

1 change to the Erivedge label since 2025, none of them to the indications. Newest first, in the words of EMA's record of each procedure.

Changes